|
|
Article: Positive results reported from first phase III clinical trial with indiplon-IR.
- Article from:
- Biotech Week
- Article date:
- January 1, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 JAN 1 - (NewsRx.com & NewsRx.net) -- Neurocrine Biosciences, Inc., (NBIX) announced positive results from the company's first phase III clinical trial with indiplon-IR capsules, achieving both primary and secondary endpoints of sleep initiation.
The study enrolled 593 subjects with transient insomnia.
Results demonstrated that indiplon-IR was safe, well tolerated, and effective in these subjects with transient insomnia, achieving rapid sleep induction without next day residual effects.
The study was a randomized, double-blind, placebo-controlled, parallel group phase III clinical trial designed to assess the safety and efficacy of two dose ...